Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.56 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.56 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.56 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5390931 | 0.99 | MEN1 (0.75) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5379835 | 0.98 | MEN1 (0.77) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5391354 | 0.96 | MEN1 (0.82) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5391069 | 0.87 | MEN1 (0.70) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL29356577 | 0.87 | MEN1 (1.00) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL1801637 | 0.87 | MEN1 (1.00) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL4859760 | 0.86 | MEN1 (0.64) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5384161 | 0.86 | MEN1 (0.62) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5392733 | 0.85 | MEN1 (0.82) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL29376205 | 0.85 | MAP2K1 (0.76) | MEN1KMT2ATDP1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | claimed |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2005-03-03 | — | — | US | claimed |
| EP-0993439-B1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | BARRETT STEPHEN DOUGLAS (US) | 2003-04-24 | — | — | US | claimed |
| JP-2003504400-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1202726-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | disclosed |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2005-03-03 | — | — | US | disclosed |
| US-6821963-B2 | PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES INHIBIT CERTAIN DUAL SPECIFICITY KINASE ENZYMES INVOLVED IN PROLIFERATIVE DISEASES SUCH AS CANCER, PSORIASIS AND RESTENOSIS; INHIBIT THE PHOSPHORYLATION OF MAP KINASE BY MEK | WARNER-LAMBERT COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-0993439-B1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | BARRETT STEPHEN DOUGLAS (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1202726-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | MAP2K2, MAP2K7, MAP2K1 | MEN1 4468/4885KMT2A 1805/4885TDP1 1875/4885 |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | MEN1 3273/4885KMT2A 1612/4885TDP1 1694/4885 |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | MEN1 3273/4885KMT2A 1612/4885TDP1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.